DNLI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Denali Therapeutics Inc (DNLI) is not an immediate buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has a solid cash reserve and some positive analyst ratings, insider selling, recent stock offering, and lack of strong proprietary trading signals suggest waiting for a better entry point.
The technical indicators show a mixed picture. The MACD is positive and expanding, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the RSI is neutral at 60.364, and the stock is trading near a resistance level (R1: 22.017) with a pivot at 20.496. The stock's recent price action (-3.90% in regular market hours) suggests some weakness.
Strong cash reserves of $966.2 million as of December 31,
Positive long-term analyst sentiment, with price targets as high as $40 and expectations of strong biotech performance in
Bullish moving averages and a positively expanding MACD.
Insider selling has increased significantly (844.50% over the last month).
A recent stock offering priced at $17.50 per share may pressure the stock price in the short term.
Wolfe Research's neutral rating and no price target indicate limited confidence in the stock's immediate upside.
Lack of recent congress trading data or influential figure activity.
In Q4 2025, Denali Therapeutics reported a net income of -$128.4 million, an improvement of 11.93% YoY. EPS improved to -$0.73, up 8.96% YoY. However, revenue and gross margin remain at 0, indicating the company is not yet generating significant income from operations.
Analyst ratings are mixed but lean positive for the long term. Morgan Stanley raised its price target to $40 with an Overweight rating, and UBS has a Buy rating with a $25 price target. However, Wolfe Research initiated coverage with a neutral Peer Perform rating, and Wedbush lowered its price target to $30 from $31 due to a recent stock offering.
